Abstract | OBJECTIVES: METHODS: A total of 355 pPCI-treated STEMI patients were randomized to either IC or IV bolus abciximab followed by a 12-hour IV infusion. Patients were followed for 1 year to observe mortality, TVR or myocardial infarction (MI) and the combination of these. RESULTS: The two treatment arms (IV, n = 170; IC, n = 185) were similar with regard to baseline characteristics. Mortality was reduced from 10% in the IV group to 2.7% in the IC group (p = 0.004). TVR and MI were also reduced with IC administration (TVR: 14.1 vs. 7.6%, p = 0.04; MI: 11.8 vs. 5.4%, p = 0.03). Consequently, patients in the IC treatment arm had a relative risk reduction of 55% for the combined endpoint after 1 year (p = 0.002) compared to the IV treatment arm. CONCLUSIONS: In pPCI-treated STEMI patients treated with abciximab, IC bolus administration resulted in a significant reduction in mortality, TVR and MI compared to IV bolus administration.
|
Authors | Allan Zeeberg Iversen, Soeren Galatius, Ulrik Abildgaard, Anders Galloe, Peter Riis Hansen, Sune Pedersen, Thomas Engstroem, Jan Skov Jensen |
Journal | Cardiology
(Cardiology)
Vol. 120
Issue 1
Pg. 43-9
( 2011)
ISSN: 1421-9751 [Electronic] Switzerland |
PMID | 22122887
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2011 S. Karger AG, Basel. |
Chemical References |
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
- Platelet Aggregation Inhibitors
- Abciximab
|
Topics |
- Abciximab
- Aged
- Angioplasty, Balloon, Coronary
(methods)
- Antibodies, Monoclonal
(administration & dosage)
- Combined Modality Therapy
- Female
- Humans
- Immunoglobulin Fab Fragments
(administration & dosage)
- Infusions, Intra-Arterial
- Infusions, Intravenous
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Myocardial Infarction
(therapy)
- Myocardial Revascularization
(methods)
- Platelet Aggregation Inhibitors
(administration & dosage)
- Prospective Studies
- Recurrence
- Treatment Outcome
|